You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCevimeline
Accession NumberDB00185  (APRD00224)
TypeSmall Molecule
GroupsApproved
DescriptionCevimeline is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors. It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome. [Wikipedia]
Structure
Thumb
Synonyms
2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
Cevimelina
Cevimelinum
Sni 2011
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CevimelineCapsule30 mg/1OralRanbaxy Pharmaceuticals Inc.2012-10-07Not applicableUs
Cevimeline HydrochlorideCapsule30 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
EvoxacCapsule30 mg/1OralSTAT Rx USA LLC2000-01-11Not applicableUs
EvoxacCapsule30 mg/1OralDaiichi Sankyo Pharma Development2000-01-12Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cevimeline HydrochlorideCapsule30 mg/1OralPACK Pharmaceuticals, LLC2014-06-17Not applicableUs
Cevimeline HydrochlorideCapsule30 mg/1OralIngenus Pharmaceuticals Nj, Llc2014-06-17Not applicableUs
Cevimeline HydrochlorideCapsule30 mg/1OralApotex Corp.2012-10-08Not applicableUs
Cevimeline HydrochlorideCapsule30 mg/1OralAvera Mc Kennan Hospital2015-10-30Not applicableUs
Cevimeline HydrochlorideCapsule30 mg/1OralRoxane Laboratories, Inc.2013-07-08Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
SaligrenNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Cevimeline hydrochloride
Thumb
  • InChI Key: WUTYZMFRCNBCHQ-PSASIEDQSA-N
  • Monoisotopic Mass: 199.103084861
  • Average Mass: 199.313
DBSALT000805
Categories
UNIIK9V0CDQ56E
CAS number107233-08-9
WeightAverage: 199.313
Monoisotopic: 199.103084861
Chemical FormulaC10H17NOS
InChI KeyWUTYZMFRCNBCHQ-LHIURRSHSA-N
InChI
InChI=1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8?,10-/m1/s1
IUPAC Name
(2R)-5'-methyl-4-azaspiro[bicyclo[2.2.2]octane-2,2'-[1,4]oxathiolane]
SMILES
CC1O[C@@]2(CS1)CN1CCC2CC1
Pharmacology
IndicationFor the treatment of symptoms of dry mouth in patients with Sjögren's Syndrome.
Structured Indications
PharmacodynamicsCevimeline is a cholinergic agonist which binds to muscarinic receptors. Muscarinic agonists in sufficient dosage can increase secretion of exocrine glands, such as salivary and sweat glands and increase tone of the smooth muscle in the gastrointestinal and urinary tracts.
Mechanism of actionMuscarinic agonists such as cevimeline bind and activate the muscarinic M1 and M3 receptors. The M1 receptors are common in secretory glands (exocrine glands such as salivary and sweat glands), and their activation results in an increase in secretion from the secretory glands. The M3 receptors are found on smooth muscles and in many glands which help to stimulate secretion in salivary glands, and their activation generally results in smooth muscle contraction and increased glandular secretions. Therefore, as saliva excretion is increased, the symptoms of dry mouth are relieved.
TargetKindPharmacological actionActionsOrganismUniProt ID
Muscarinic acetylcholine receptor M3Proteinyes
agonist
HumanP20309 details
Muscarinic acetylcholine receptor M1Proteinyes
agonist
HumanP11229 details
Related Articles
AbsorptionRapidly absorbed with peak concentration after 1.5 to 2 hours
Volume of distribution
  • 6 L/kg
Protein binding< 20%
Metabolism

Primarily hepatic, isozymes CYP2D6 and CYP3A4 are responsible for the metabolism of cevimeline. Approximately 44.5% of the drug is converted to cis and trans-sulfoxide, 22.3% to glucuronic acid conjugate, and 4% to N-oxide of cevimeline. Approximately 8% of the trans-sulfoxide metabolite is then converted into the corresponding glucuronic acid conjugate.

SubstrateEnzymesProduct
Cevimeline
cevimeline trans-sulfoxideDetails
Cevimeline
cevimeline cis-sulfoxideDetails
Cevimeline
cevimeline cis-sulfoxidationDetails
Cevimeline
cevimeline N-oxideDetails
Cevimeline
Not Available
Glucuronic acidDetails
Route of eliminationAfter 24 hours, 84% of a 30 mg dose of cevimeline was excreted in urine.
Half life5 ± 1 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Cevimeline.Experimental
AbirateroneThe serum concentration of Cevimeline can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Cevimeline.Approved
AlprenololThe risk or severity of adverse effects can be increased when Alprenolol is combined with Cevimeline.Approved, Withdrawn
AmbenoniumThe risk or severity of adverse effects can be increased when Ambenonium is combined with Cevimeline.Approved
AmiodaroneThe metabolism of Cevimeline can be decreased when combined with Amiodarone.Approved, Investigational
Aop200704The risk or severity of adverse effects can be increased when Aop200704 is combined with Cevimeline.Investigational
AprepitantThe serum concentration of Cevimeline can be increased when it is combined with Aprepitant.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Cevimeline.Approved
ArtemetherThe metabolism of Cevimeline can be decreased when combined with Artemether.Approved
AtazanavirThe metabolism of Cevimeline can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Cevimeline.Approved
AtomoxetineThe metabolism of Cevimeline can be decreased when combined with Atomoxetine.Approved
BefunololThe risk or severity of adverse effects can be increased when Befunolol is combined with Cevimeline.Experimental
BetaxololThe metabolism of Cevimeline can be decreased when combined with Betaxolol.Approved
BevantololThe risk or severity of adverse effects can be increased when Bevantolol is combined with Cevimeline.Approved
BexaroteneThe serum concentration of Cevimeline can be decreased when it is combined with Bexarotene.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Cevimeline.Approved
BoceprevirThe metabolism of Cevimeline can be decreased when combined with Boceprevir.Approved
BopindololThe risk or severity of adverse effects can be increased when Bopindolol is combined with Cevimeline.Approved
BortezomibThe metabolism of Cevimeline can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Cevimeline can be decreased when it is combined with Bosentan.Approved, Investigational
BucindololThe risk or severity of adverse effects can be increased when Bucindolol is combined with Cevimeline.Investigational
BufuralolThe risk or severity of adverse effects can be increased when Bufuralol is combined with Cevimeline.Experimental, Investigational
BupranololThe risk or severity of adverse effects can be increased when Bupranolol is combined with Cevimeline.Approved
BupropionThe metabolism of Cevimeline can be decreased when combined with Bupropion.Approved
CarbamazepineThe metabolism of Cevimeline can be increased when combined with Carbamazepine.Approved, Investigational
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Cevimeline.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Cevimeline.Approved, Investigational
CelecoxibThe metabolism of Cevimeline can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Celiprolol is combined with Cevimeline.Approved, Investigational
CeritinibThe serum concentration of Cevimeline can be increased when it is combined with Ceritinib.Approved
ChloroquineThe metabolism of Cevimeline can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe metabolism of Cevimeline can be decreased when combined with Chlorpromazine.Approved, Vet Approved
CholecalciferolThe metabolism of Cevimeline can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Cevimeline can be decreased when combined with Cimetidine.Approved
CimetropiumCevimeline may decrease the anticholinergic activities of Cimetropium.Experimental
CinacalcetThe metabolism of Cevimeline can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Cevimeline can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Cevimeline can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Cevimeline can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Cevimeline can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe metabolism of Cevimeline can be decreased when combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe metabolism of Cevimeline can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Cevimeline can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Cevimeline can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Cevimeline can be decreased when combined with Cocaine.Approved, Illicit
ConivaptanThe serum concentration of Cevimeline can be increased when it is combined with Conivaptan.Approved, Investigational
CoumaphosThe risk or severity of adverse effects can be increased when Coumaphos is combined with Cevimeline.Vet Approved
CrizotinibThe metabolism of Cevimeline can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Cevimeline can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Cevimeline can be decreased when it is combined with Dabrafenib.Approved
DarifenacinThe metabolism of Cevimeline can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Cevimeline can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Cevimeline can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Decamethonium is combined with Cevimeline.Approved
DeferasiroxThe serum concentration of Cevimeline can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Cevimeline can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Demecarium is combined with Cevimeline.Approved
DesipramineThe metabolism of Cevimeline can be decreased when combined with Desipramine.Approved
DexamethasoneThe serum concentration of Cevimeline can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DichlorvosThe risk or severity of adverse effects can be increased when Dichlorvos is combined with Cevimeline.Vet Approved
DihydroergotamineThe metabolism of Cevimeline can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Cevimeline can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Cevimeline can be decreased when combined with Diphenhydramine.Approved
DonepezilThe risk or severity of adverse effects can be increased when Donepezil is combined with Cevimeline.Approved
DoxycyclineThe metabolism of Cevimeline can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Cevimeline can be decreased when combined with Dronedarone.Approved
DuloxetineThe metabolism of Cevimeline can be decreased when combined with Duloxetine.Approved
EchothiophateThe risk or severity of adverse effects can be increased when Echothiophate is combined with Cevimeline.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Edrophonium is combined with Cevimeline.Approved
EfavirenzThe serum concentration of Cevimeline can be decreased when it is combined with Efavirenz.Approved, Investigational
EliglustatThe metabolism of Cevimeline can be decreased when combined with Eliglustat.Approved
EnzalutamideThe serum concentration of Cevimeline can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Cevimeline can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Cevimeline can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Cevimeline.Approved
EtravirineThe serum concentration of Cevimeline can be decreased when it is combined with Etravirine.Approved
FenthionThe risk or severity of adverse effects can be increased when Fenthion is combined with Cevimeline.Vet Approved
FluconazoleThe metabolism of Cevimeline can be decreased when combined with Fluconazole.Approved
FluoxetineThe metabolism of Cevimeline can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluvoxamineThe metabolism of Cevimeline can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Cevimeline can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Cevimeline can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Cevimeline can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Cevimeline can be increased when it is combined with Fusidic Acid.Approved
GalantamineThe risk or severity of adverse effects can be increased when Galantamine is combined with Cevimeline.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Cevimeline.Approved
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Ginkgo biloba is combined with Cevimeline.Approved, Nutraceutical
HaloperidolThe metabolism of Cevimeline can be decreased when combined with Haloperidol.Approved
Huperzine AThe risk or severity of adverse effects can be increased when Huperzine A is combined with Cevimeline.Investigational
IdelalisibThe serum concentration of Cevimeline can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Cevimeline can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Cevimeline can be decreased when combined with Imipramine.Approved
IndenololThe risk or severity of adverse effects can be increased when Indenolol is combined with Cevimeline.Withdrawn
IndinavirThe metabolism of Cevimeline can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Cevimeline can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Cevimeline.Approved, Withdrawn
IsoniazidThe metabolism of Cevimeline can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Cevimeline can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Cevimeline can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Cevimeline can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Cevimeline can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Cevimeline.Approved
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Cevimeline.Approved
LopinavirThe metabolism of Cevimeline can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Cevimeline can be decreased when combined with Lorcaserin.Approved
LovastatinThe metabolism of Cevimeline can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Cevimeline can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Cevimeline can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Cevimeline can be decreased when combined with Lumefantrine.Approved
MalathionThe risk or severity of adverse effects can be increased when Malathion is combined with Cevimeline.Approved, Investigational
MefloquineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Cevimeline.Approved
MemantineThe risk or severity of adverse effects can be increased when Memantine is combined with Cevimeline.Approved, Investigational
MethadoneThe metabolism of Cevimeline can be decreased when combined with Methadone.Approved
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Methanesulfonyl Fluoride is combined with Cevimeline.Investigational
MethotrimeprazineThe metabolism of Cevimeline can be decreased when combined with Methotrimeprazine.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Cevimeline.Approved
MetoprololThe metabolism of Cevimeline can be decreased when combined with Metoprolol.Approved, Investigational
MifepristoneThe serum concentration of Cevimeline can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Cevimeline.Approved
MirabegronThe metabolism of Cevimeline can be decreased when combined with Mirabegron.Approved
MitotaneThe serum concentration of Cevimeline can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Cevimeline can be decreased when it is combined with Modafinil.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Cevimeline.Approved
NafcillinThe serum concentration of Cevimeline can be decreased when it is combined with Nafcillin.Approved
NefazodoneThe metabolism of Cevimeline can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Cevimeline can be decreased when combined with Nelfinavir.Approved
NeostigmineThe risk or severity of adverse effects can be increased when Neostigmine is combined with Cevimeline.Approved, Vet Approved
NetupitantThe serum concentration of Cevimeline can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Cevimeline can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Cevimeline can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Cevimeline can be decreased when combined with Nilotinib.Approved, Investigational
OlaparibThe metabolism of Cevimeline can be decreased when combined with Olaparib.Approved
OsimertinibThe serum concentration of Cevimeline can be increased when it is combined with Osimertinib.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Cevimeline.Approved
PalbociclibThe serum concentration of Cevimeline can be increased when it is combined with Palbociclib.Approved
PanobinostatThe serum concentration of Cevimeline can be increased when it is combined with Panobinostat.Approved, Investigational
ParoxetineThe metabolism of Cevimeline can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Cevimeline can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Cevimeline.Approved, Investigational
PentobarbitalThe metabolism of Cevimeline can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Cevimeline can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Cevimeline can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Physostigmine is combined with Cevimeline.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Cevimeline.Approved
PosaconazoleThe metabolism of Cevimeline can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololThe risk or severity of adverse effects can be increased when Practolol is combined with Cevimeline.Approved
PrimidoneThe metabolism of Cevimeline can be increased when combined with Primidone.Approved, Vet Approved
PromazineThe metabolism of Cevimeline can be decreased when combined with Promazine.Approved, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Cevimeline.Approved, Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Pyridostigmine is combined with Cevimeline.Approved
QuinidineThe metabolism of Cevimeline can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Cevimeline can be decreased when combined with Quinine.Approved
RanolazineThe metabolism of Cevimeline can be decreased when combined with Ranolazine.Approved, Investigational
RifabutinThe metabolism of Cevimeline can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Cevimeline can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Cevimeline can be increased when combined with Rifapentine.Approved
RitonavirThe metabolism of Cevimeline can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Rivastigmine is combined with Cevimeline.Approved, Investigational
RolapitantThe metabolism of Cevimeline can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Cevimeline can be decreased when combined with Ropinirole.Approved, Investigational
SaquinavirThe metabolism of Cevimeline can be decreased when combined with Saquinavir.Approved, Investigational
SertralineThe metabolism of Cevimeline can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Cevimeline can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Cevimeline can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Cevimeline can be increased when it is combined with Simeprevir.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Cevimeline.Approved
St. John's WortThe serum concentration of Cevimeline can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StiripentolThe serum concentration of Cevimeline can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Cevimeline can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrineThe risk or severity of adverse effects can be increased when Tacrine is combined with Cevimeline.Withdrawn
TelaprevirThe metabolism of Cevimeline can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Cevimeline can be decreased when combined with Telithromycin.Approved
TerbinafineThe metabolism of Cevimeline can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
ThioridazineThe metabolism of Cevimeline can be decreased when combined with Thioridazine.Approved
TiclopidineThe metabolism of Cevimeline can be decreased when combined with Ticlopidine.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Cevimeline.Approved
TipranavirThe metabolism of Cevimeline can be decreased when combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Cevimeline can be decreased when it is combined with Tocilizumab.Approved
TranylcypromineThe metabolism of Cevimeline can be decreased when combined with Tranylcypromine.Approved
TrichlorfonThe risk or severity of adverse effects can be increased when Trichlorfon is combined with Cevimeline.Vet Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Cevimeline.Approved
VenlafaxineThe metabolism of Cevimeline can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Cevimeline can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Cevimeline can be decreased when combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Cevimeline can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN07AX03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (34.3 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9899
Blood Brain Barrier+0.9823
Caco-2 permeable+0.6465
P-glycoprotein substrateSubstrate0.7063
P-glycoprotein inhibitor INon-inhibitor0.6941
P-glycoprotein inhibitor IINon-inhibitor0.9434
Renal organic cation transporterInhibitor0.6934
CYP450 2C9 substrateNon-substrate0.8083
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5719
CYP450 1A2 substrateNon-inhibitor0.8634
CYP450 2C9 inhibitorNon-inhibitor0.9047
CYP450 2D6 inhibitorNon-inhibitor0.6012
CYP450 2C19 inhibitorNon-inhibitor0.7312
CYP450 3A4 inhibitorNon-inhibitor0.9154
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7686
Ames testNon AMES toxic0.7969
CarcinogenicityNon-carcinogens0.9054
BiodegradationNot ready biodegradable0.9942
Rat acute toxicity2.7785 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6383
hERG inhibition (predictor II)Non-inhibitor0.8469
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Daiichi sankyo co ltd
Packagers
Dosage forms
FormRouteStrength
CapsuleOral30 mg/1
Prices
Unit descriptionCostUnit
Evoxac 30 mg capsule2.69USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4855290 No1992-08-302009-08-30Us
US5340821 No1993-07-072013-07-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point201-203 °C (HCl salt)Not Available
water solubilityVery solubleNot Available
logP1.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.41 mg/mLALOGPS
logP1.46ALOGPS
logP1ChemAxon
logS-1.9ALOGPS
pKa (Strongest Basic)8.59ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity55.92 m3·mol-1ChemAxon
Polarizability21.89 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as azaspirodecane derivatives. These are organic compounds containing a spirodecane moiety with at least one nitrogen atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzaspirodecane derivatives
Sub ClassNot Available
Direct ParentAzaspirodecane derivatives
Alternative Parents
Substituents
  • Azaspirodecane
  • Quinuclidine
  • Piperidine
  • Oxathiolane
  • Monothioacetal
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Azacycle
  • Thioether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Li X, Azlina A, Karabasil MR, Purwanti N, Hasegawa T, Yao C, Akamatsu T, Hosoi K: Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor agonist. Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G112-G123. doi: 10.1152/ajpgi.00359.2007. Epub 2008 May 1. [PubMed:18450949 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Fisher A, Heldman E, Gurwitz D, Haring R, Karton Y, Meshulam H, Pittel Z, Marciano D, Brandeis R, Sadot E, Barg Y, Pinkas-Kramarski R, Vogel Z, Ginzburg I, Treves TA, Verchovsky R, Klimowsky S, Korczyn AD: M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update. Ann N Y Acad Sci. 1996 Jan 17;777:189-96. [PubMed:8624083 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Washio T, Arisawa H, Kohsaka K, Yasuda H: Identification of human drug-metabolizing enzymes involved in the metabolism of SNI-2011. Biol Pharm Bull. 2001 Nov;24(11):1263-6. [PubMed:11725960 ]
  2. Washio T, Kohsaka K, Arisawa H, Masunaga H: Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs. Arzneimittelforschung. 2003;53(1):26-33. [PubMed:12608011 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Washio T, Arisawa H, Kohsaka K, Yasuda H: Identification of human drug-metabolizing enzymes involved in the metabolism of SNI-2011. Biol Pharm Bull. 2001 Nov;24(11):1263-6. [PubMed:11725960 ]
  2. Washio T, Kohsaka K, Arisawa H, Masunaga H: Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs. Arzneimittelforschung. 2003;53(1):26-33. [PubMed:12608011 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Nadp binding
Specific Function:
This protein is involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. Form I catalyzes the N-oxygenation of secondary and tertiary amines.
Gene Name:
FMO1
Uniprot ID:
Q01740
Molecular Weight:
60310.285 Da
References
  1. Washio T, Arisawa H, Kohsaka K, Yasuda H: Identification of human drug-metabolizing enzymes involved in the metabolism of SNI-2011. Biol Pharm Bull. 2001 Nov;24(11):1263-6. [PubMed:11725960 ]
  2. Washio T, Kohsaka K, Arisawa H, Masunaga H: Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs. Arzneimittelforschung. 2003;53(1):26-33. [PubMed:12608011 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23